Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEVATE-1: GSK5926371 in B-cell Driven Autoimmune Rheumatic Diseases
NCT07371468Phase 1Recruiting
- Sponsor
- GSK
- Start
- Feb 2026
- Primary completion
- Mar 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, T-cell Engagers
- Countries
- 9
01
Overview
Phase 1, open-label trial of GSK5926371 in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), idiopathic inflammatory myopathy (IIM) and 1 more (2 arms), sponsored by GSK. Primary endpoint: Number of Participants with Adverse Events (AEs) and Serious AEs (SAEs) at 196 days. Started Feb 2026; status: recruiting.
02
Drugs
GSK5926371
03
Conditions
systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)idiopathic inflammatory myopathy (IIM)Sjögren's syndrome
Beyond the preview
Go deeper on NCT07371468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07371468.